Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Aug 10, 2022 (4 years ago)

Ketorolac Tromethamine Injection

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

cGMP Deviations: deviations leading to potential cross-contamination.

Cause type: Cross-contamination

Traces of another drug - most often penicillin - got into the product from shared equipment or facilities. Even trace penicillin can trigger a severe allergic reaction in someone who was never meant to receive it. All cross-contamination recalls.

What was recalled

Ketorolac Tromethamine Injection, USP 60 mg/2 mL (30 mg/mL), packaged in 2 mL single dose vials, Rx Only, Nephron Pharmaceutical Corporation 4500 12th Street Extension West Columbia, SV 29172, NDC 0487-6232-01

Affected NDC 0487-6232-01

Compare with the code on your package — it is the most precise check available.

Drug: Ketorolac

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Ketorolac Tromethamine
NDC 00487-6232
30 mg/mL Injection
Intramuscular
Nephron Pharmaceuticals Corporation Rx
Recalling firm
Nephron Sc Inc
NDC code
0487-6232-01
Origin
SC, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1354-2022 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Ketorolac recalls

See all

Other recalls by Nephron Sc Inc

All 2022 recalls